摘要
肝纤维化是多种致病因素导致肝脏的反复慢性肝损伤,是多种慢性肝病共同的病理变化。肝星状细胞(HSC)的活化而导致细胞外基质(ECM)的沉积是肝纤维化的发病基础。磷脂酰肌醇激酶/蛋白激酶(PI3K/AKT)信号转导通路在调控HSC的活化、增殖及凋亡等方面发挥着重要作用。近年来"靶向"中药逐渐成为研究的热点,本文以中医药干预PI3K/AKT信号通路抗肝纤维化为综述,旨在指导肝纤维化治疗的用药。
Liver fibrosis is recurrent chronic liver injury in the liver from a variety of pathogenic factors,and is a common pathological change of many chronic liver diseases.The activation of hepatic stellate cells(HSCs)leads to the deposition of extracellular matrix,and that was the pathogenesis of liver fibrosis.Phosphatidylinositol kinase/protein kinase(PI3K/AKT)signal transduction pathway plays an important role in the regulation of HSC activation,proliferation and apoptosis.In recent years,“targeting”traditional Chinese medicine has gradually become a hot topic.In this paper,intervening PI3K/AKT signaling pathway against liver fibrosis with TCM medicine were reviewed,to guiding medication of liver fibrosis.
出处
《中医临床研究》
2018年第8期146-148,共3页
Clinical Journal Of Chinese Medicine
基金
河南省中医药科学研究专项课题(2014ZY02011)
河南中医药大学博士科研基金(BSJJ2014-11)
